Cheyne Capital Management (UK)’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Cheyne Capital Management (UK)’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-41,320	Closed	-$709K	–	37
2015 Q4	$709K	Sell	41,320 -80,219	-66%	-$1.91M	0.38%	24
2015 Q3	$2.56M	Sell	121,539 -26,866	-18%	-$921K	1.2%	11
2015 Q2	$7.34M	Sell	148,405 -36	-0%	-$2.15K	2.37%	6
2015 Q1	$11.6M	Buy	148,441 +42,575	+40%	+$2.64M	2.8%	11
2014 Q4	$6.42M	Buy	105,866 +36,502	+53%	+$1.83M	1.69%	11
2014 Q3	$2.96M	Buy	+69,364	New	+$3.72M	1.05%	15

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cheyne Capital Management (UK)'s OREX Position: Q1 2016 in Review

Cheyne Capital Management (UK) sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 41,320 shares — an estimated $709K sold.

Cheyne Capital Management (UK) first reported a position in OREX in Q3 2014 and held it in 6 quarters. The position peaked at $11.6M in Q1 2015. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

Cheyne Capital Management (UK) reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Cheyne Capital Management (UK) sold 41,320 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $709K.
Cheyne Capital Management (UK) first reported a position in Orexigen Therapeutics, Inc. in Q3 2014 and held it in 6 quarters.
Cheyne Capital Management (UK)'s Orexigen Therapeutics, Inc. position peaked at $11.6M in Q1 2015.
104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2016, filed 18 Apr 2016.